These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 15153786

  • 41. Specificity and clinical performance of two commercial TRACP 5b immunoassays.
    Ylipahkala H, Fagerlund KM, Janckila AJ, Houston B, Laurie D, Halleen JM.
    Clin Lab; 2009; 55(5-6):223-8. PubMed ID: 19728556
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
    Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT.
    Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Significance of serum TRACP in rheumatoid arthritis.
    Janckila AJ, Neustadt DH, Yam LT.
    J Bone Miner Res; 2008 Aug; 23(8):1287-95. PubMed ID: 18410226
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
    Jung K, Lein M, Ringsdorf M, Roigas J, Schnorr D, Loening SA, Staack A.
    J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
    [Abstract] [Full Text] [Related]

  • 53. Tartrate-resistant acid phosphatase (TRAP) as a serum marker for bone resorption in breast cancer patients with bone metastases.
    Tauchert S, di Liberto A, Cordes T, Thill M, Salehin D, Friedrich M.
    Clin Exp Obstet Gynecol; 2009 Oct; 36(4):219-25. PubMed ID: 20101852
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations.
    Cavalier E, Lukas P, Delanaye P.
    Clin Chem Lab Med; 2022 Feb 23; 60(3):394-400. PubMed ID: 34907694
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Survival markers related to bone metastases in prostate cancer.
    Salminen EK, Kallioinen MJ, Ala-Houhala MA, Vihinen PP, Tiitinen SL, Varpula M, Vahlberg TJ.
    Anticancer Res; 2006 Feb 23; 26(6C):4879-84. PubMed ID: 17214355
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients.
    Cao Y, Liu X, Xu H.
    Clin Lab; 2012 Feb 23; 58(7-8):845-50. PubMed ID: 22997989
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.